Replies to post #208157 on Biotech Values

[DewDiligence]

...my takeaway at this point is interchangeability will be governed more by trials than the lab.

I don't agree. If a company doesn't have the analytical capabilities to justify consideration for interchangeable status, no amount of clinical-trial work will be sufficient to compensate.